ACE-031 (1mg)

ACE-031 is a recombinant fusion protein peptide, synthesized and lyophilized in the USA. Batch purity is confirmed by HPLC-MS and independently verified by a third-party laboratory.

Laboratory work with ACE-031 (1mg) emphasizes reproducible reconstitution and handling protocols.

Current investigation of ACE-031 (1mg) focuses on its stability profile and signaling activity in controlled models.

ACE-031 (1mg) is a lyophilized research peptide supplied for in-vitro laboratory investigation.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with ACE-031 (1mg). Summaries are provided for orientation only and reflect the cited sources.

A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers^[1] — This study evaluated the safety and pharmacodynamics of the muscle regulator ACE-031, a myostatin inhibitor, in healthy volunteers. The authors report findings from a single ascending-dose design. The results informed the early clinical development of ACE-031 as an agent intended to increase muscle mass. (Muscle & Nerve 2013)

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial^[2] — This randomized, placebo-controlled clinical trial assessed the myostatin inhibitor ACE-031 in ambulatory boys with Duchenne muscular dystrophy. The authors report effects of treatment on measures related to muscle. The study provided clinical data on ACE-031's use in this patient population. (Muscle & Nerve 2017)

Targeting the Activin Type IIB Receptor to Improve Muscle Mass and Function in the mdx Mouse Model of Duchenne Muscular Dystrophy^[3] — This study investigated blockade of the activin type IIB receptor as a strategy to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. The authors report that targeting this receptor improved muscle outcomes. These findings provide preclinical support for the approach embodied by ACE-031. (The American Journal of Pathology 2011)

References

1. Attie KM, et al.. "A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers." Muscle & Nerve. 2013. pubmed.ncbi.nlm.nih.gov/23169607/
2. Campbell C, et al.. "Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial." Muscle & Nerve. 2017. pubmed.ncbi.nlm.nih.gov/27462804/
3. Pistilli EE, et al.. "Targeting the Activin Type IIB Receptor to Improve Muscle Mass and Function in the mdx Mouse Model of Duchenne Muscular Dystrophy." The American Journal of Pathology. 2011. pmc.ncbi.nlm.nih.gov/articles/PMC3069867/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.